Neumora Therapeutics Inc. Common Stock (NMRA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Neumora Therapeutics Inc. Common Stock (NMRA) is down 2.2% since the beginning of the year. At $2 per share, NMRA is trading 52.1% below its 52-week high of $4.

Neumora Therapeutics Inc. Common Stock (NMRA) has returned -2.23% so far this year and 135.50% over the past 12 months.

Based on dividend-adjusted daily data since Sep 14, 2023, NMRA's average daily return is -0.05%, while the average monthly return is +1.17%. At this rate, an investment would double in approximately 5.0 years.

Historically, 41% of months were positive and 59% were negative. The best month was Jul 2025 with a return of +167.3%, while the worst month was Jan 2025 at -81.8%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 5 months.

On a daily basis, NMRA closed higher 48% of trading days. The best single day was Oct 23, 2025 with a return of +35.1%, while the worst single day was Jan 2, 2025 at -81.4%.

Neumora Therapeutics Inc. Common Stock has an annualized alpha of -34.84%, beta of 1.44, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since September 15, 2023.

• This stock participated in 328.79% of S&P 500 Index downside but only -17.56% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NMRA ranks 78 for risk / return — better than 78% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Neumora Therapeutics Inc. Common Stock (NMRA) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Neumora Therapeutics Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Neumora Therapeutics Inc. Common Stock was 96.89%, occurring on May 14, 2025. The portfolio has not yet recovered.

The current Neumora Therapeutics Inc. Common Stock drawdown is 91.14%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Neumora Therapeutics Inc. Common Stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Neumora Therapeutics Inc. Common Stock is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.